Epilepsy Trial, Recruiting NCT07640191 Sponsor: iVEAcare Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT07640191
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 4 to 75 years.
  • People who have focal (partial) seizures or generalised seizures that have not been controlled by anti-seizure medications.
  • People who have had at least 4 seizures per month on average over the 90 days before enrolling.
  • People diagnosed with Drug Resistant Epilepsy, meaning seizures have not been controlled despite trying two or more appropriate anti-seizure medications.
  • People whose anti-seizure medications have been at a stable, consistent dose for at least 30 days before enrolling, and who are able to keep that dose stable through the first 6 months after the device is activated (emergency rescue medications may still be used when needed).

Who may not be able to join:

  • People who are not suitable for the surgery required to implant the iVEAcare Neuromodulation System.
  • People with a worsening neurological condition or another deteriorating medical condition.
  • People who have previously had their left vagus nerve surgically cut.
  • People who currently require diathermy treatment anywhere in their body (including short-wave, microwave, or therapeutic ultrasound diathermy).
  • People with known damage to the vagus nerve, or other reasons why the left vagus nerve would not be suitable for the implant.
  • People with paralysis of the vocal cords.
  • People who have had brain surgery for epilepsy within 6 months before the baseline study visit.
  • People who already have certain implanted or external electrical devices, including a cardiac defibrillator, pacemaker, deep brain stimulator, responsive neurostimulator, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, carotid baroreceptor stimulator, cochlear implant, or an external nerve stimulation device such as a TENS machine. Note: People who already have an approved vagus nerve stimulation (VNS) system for drug-resistant epilepsy and whose device is nearing end of life may be considered for a generator replacement only — confirm with the trial site for details.
  • People who are pregnant or planning to become pregnant within the next 12 months.
  • People with any currently active cancer, not including skin cancer.
  • People with an active infection near the implant site or anywhere in the body.
  • People with poorly controlled Type 1 or Type 2 diabetes, as measured by a specific blood sugar level marker (HbA1c above a certain threshold) — confirm the exact threshold with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Terence O'Brien, MD, The Alfred Hospital and Monash University

Phone: +1 651 728 4832

Australian sites

The Mater, South Brisbane, Queensland
07 3163 2850
The Alfred Hospital, Melbourne, Victoria
+61 3 9076 2029

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
iVEAcare
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 July 2027

Where this trial is recruiting

🇦🇺 Australia

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

iVEAcare Neuromodulation System Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov